Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-Glucose Transporter 2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Looking for participantsNCT07292909
What this trial is testing

Effect of Empagliflozin on Inflammation

Who this might be right for
CAD - Coronary Artery DiseaseInflamationPCI+1 more
Hotel Dieu de France Hospital 100
Testing effectiveness (Phase 2)Study completedNCT05254626
What this trial is testing

Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis

Who this might be right for
Non-alcoholic Steatohepatitis
Cairo University 100
Early research (Phase 1)Study completedNCT02696941
What this trial is testing

SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis

Who this might be right for
Non-alcoholic Fatty Liver Disease
University of Oxford 20
Early research (Phase 1)Study completedNCT04450563
What this trial is testing

Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System

Who this might be right for
Type 1 Diabetes
McGill University 25
Not applicableStudy completedNCT02857764
What this trial is testing

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Who this might be right for
Diabetes Mellitus, Type 2
Janssen Research & Development, LLC 127,690
Testing effectiveness (Phase 2)Study completedNCT04956263
What this trial is testing

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

Who this might be right for
DiabetesDiabetes Mellitus, Type 1Type1diabetes+1 more
Youngene Therapeutics Inc., Ltd. 19
Testing effectiveness (Phase 2)Looking for participantsNCT06845163
What this trial is testing

Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

Who this might be right for
Diabetic Macular EdemaCenter-involved Diabetic Macular Edema
Alexandria University 56
Testing effectiveness (Phase 2)UnknownNCT06341842
What this trial is testing

Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity

Who this might be right for
Breast Cancer
Fondazione IRCCS Policlinico San Matteo di Pavia 316
Testing effectiveness (Phase 2)WithdrawnNCT05058859
What this trial is testing

Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics

Who this might be right for
Cystinuria
University of California, San Francisco
Large-scale testing (Phase 3)Study completedNCT04965935
What this trial is testing

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

Who this might be right for
Kidney Transplant RecipientsPost-transplant Diabetes MellitusType 2 Diabetes
University Health Network, Toronto 52
Not applicableActive Not RecruitingNCT07450417
What this trial is testing

Effect of Early Empagliflozin Initiation in Cardiogenic Shock.

Who this might be right for
Cardiogenic Shock
Central Hospital, Nancy, France 418
Post-approval studies (Phase 4)Looking for participantsNCT07700940
What this trial is testing

The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population

Who this might be right for
Lupus Nephritis (LN)
Ahmed Yehia Ismail 66
Not applicableNot Yet RecruitingNCT06838507
What this trial is testing

Incidence, Characterisation and Outcome-relevance of Perioperative SGLT2 Inhibitor Associated Ketoacidosis

Who this might be right for
SGLT2 InhibitorKetoacidosis, Eugylcemic
Heinrich-Heine University, Duesseldorf 2,000
Not applicableNot Yet RecruitingNCT07472920
What this trial is testing

Empagliflozin Adjunctive Therapy in Bipolar Depression

Who this might be right for
Bipolar DisorderBipolar DepressionInsulin Resistance
University of Sao Paulo 20
Post-approval studies (Phase 4)Study completedNCT03030235
What this trial is testing

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

Who this might be right for
Chronic Heart Failure With Preserved Systolic Function
Saint Luke's Health System 324
Large-scale testing (Phase 3)Looking for participantsNCT07653477
What this trial is testing

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

Who this might be right for
Type 2 Diabetes
The United Bio-Technology (Hengqin) Co., Ltd. 956
Not applicableActive Not RecruitingNCT07478575
What this trial is testing

Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure

Who this might be right for
Heart FailureAnemiaRenal Insufficiency
University Medical Centre Ljubljana 85
Large-scale testing (Phase 3)Not Yet RecruitingNCT07156539
What this trial is testing

HS-20094 in Patients With T2DM

Who this might be right for
Type 2 Diabetes
Jiangsu Hansoh Pharmaceutical Co., Ltd. 546
Not applicableStudy completedNCT07338331
What this trial is testing

Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease

Who this might be right for
Diabete Type 2Non Alcoholic Fatty Liver
Galala University 80
Not applicableLooking for participantsNCT07444203
What this trial is testing

Transformative Research in Diabetic Nephropathy 2.0

Who this might be right for
Diabetic NephropathiesKidney DiseasesRenal Insufficiency, Chronic+1 more
University of Pennsylvania 200
Next Page